(Q38350347)

2 September 2017

1 reference

title

Pharmacologic treatment of type 2 diabetes: oral medications (English)

1 reference

2 September 2017

0 references

Linda Tran

1

1 reference

2 September 2017

Angela Zielinski

2

1 reference

2 September 2017

Arpi H Roach

3

1 reference

2 September 2017

Jennifer A Jende

4

1 reference

2 September 2017

Ann Marie Householder

5

1 reference

2 September 2017

Emily E Cole

6

1 reference

2 September 2017

Shuruq A Atway

7

1 reference

2 September 2017

Melinda Amornyard

8

1 reference

2 September 2017

Mallory L Accursi

9

1 reference

2 September 2017

Suzanna W Shieh

10

1 reference

2 September 2017

Erin E Thompson

11

1 reference

2 September 2017

language of work or name

English

0 references

publication date

9 February 2015

1 reference

Annals of Pharmacotherapy

2 September 2017

1 reference

2 September 2017

49

1 reference

2 September 2017

5

1 reference

2 September 2017

540-556

1 reference

Diagnosis and Classification of Diabetes Mellitus

2 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Lactic acidosis rates in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Evaluation of vitamin B12 monitoring in a veteran population on long-term, high-dose metformin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Revisiting Metformin: Annual Vitamin B12 Supplementation may become Mandatory with Long-Term Metformin Use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Acarbose in the treatment of elderly patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Miglitol combined with metformin improves glycaemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

A prospective, randomized, open-label study comparing the efficacy and safety of preprandial and prandial insulin in combination with acarbose in elderly, insulin-requiring patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Bone loss and fracture risk associated with thiazolidinedione therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Diurnal glucose profiles using continuous glucose monitoring to identify the glucose-lowering characteristics of colesevelam HCl (Welchol).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

The glucose and lipid effects of colesevelam as monotherapy in drug-naïve type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014558289

21 January 2018

Identifiers

DOI

10.1177/1060028014558289

1 reference

2 September 2017

1 reference